Pfizer (PFE) announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Metsera (MTSR). The termination of the waiting period under the HSR Act satisfies the regulatory review requirements under the previously announced proposed acquisition of Metsera, which was set to expire on November 7. The Fly notes that Novo Nordisk (NVO) is also attempting to acquire Metsera.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Midday Fly By: Apple, Amazon upbeat reports lift Nasdaq
- Pfizer Could Call on Best Buddy Trump to Help Win $8.5B Novo Nordisk Bidding War
- Trump Trade: China to work with U.S. to resolve TikTok issue
- Pfizer could use Trump connections in Metsera bid, Reuters reports
- M&A War: Pfizer Blasts Rival Novo Nordisk for “Reckless” $8.5B Hijack of Metsera Obesity Deal